Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Solitary Fibrous Tumor, Pleural 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Pemetrexed 7Cisplatin 7Cyclophosphamide 5pembrolizumab 4fludarabine 4Platinum 3Drug Therapy 3aldesleukin 2Nivolumab 2Ipilimumab 2Interleukin-2 21,2-diaminocyclohexaneplatinum II citrate 2vatalanib 1spartalizumab 1regorafenib 1napabucasin 1methoxyamine 1fludarabine phosphate 1enzalutamide 1cediranib 1avelumab 1atezolizumab 1anetumab ravtansine 1Vorinostat 1Thiostrepton 1Tetrahydrouridine 1Radiosurgery 1Megestrol Acetate 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma, Malignant × cediranib × Clear all
NCT01064648 2026-05-29

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
117 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡